A Single-Arm, Multicenter, Open-Label, Phase 2 Study of;Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab;(IMC-11F8) in the First-Line Treatment of Patients With;Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) - I4X-MC-JFCK

Eli Lilly0 个研究点目标入组 7 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Histologically or cytologically confirmed squamous NSCLC;
•Stage IV disease at time of study entry based on AJCC 7th edition;
•Measurable disease at time of study entry as defined by RECIST 1.1;
•The patient has an Eastern Cooperative Oncology Group performance status score of 0-1, the patient has an estimated life expectancy of at least 12 weeks and in the judgment of the investigator, will be able to complete at least 2 cycles of treatment.

•Nonsquamous NSCLC;
•Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor;
•Previous chemotherapy for NSCLC;
•Major surgery or received any investigational therapy in the 4 weeks prior to study enrollment;
•Chest irradiation within 12 weeks prior to study enrollment (except palliative irradiation of bone lesions,
•which is allowed);
•Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants (Patients who have completed radiotherapy for brain metastases at least 4 weeks prior to receiving treatment, who are now nonsymptomatic and have not required treatment with steroids or anticonvulsants during the 2 weeks prior to receiving treatment, are eligible.)

发起方